Dissacharide Patents (Class 514/53)
  • Patent number: 11510980
    Abstract: The invention relates to brartemicin analogues of Formula (IV) and their uses. These compounds are potent Mincle agonists and Th1-stimulating vaccine adjuvants.
    Type: Grant
    Filed: November 2, 2018
    Date of Patent: November 29, 2022
    Assignees: VICTORIA LINK LTD., OSAKA UNIVERSITY
    Inventors: Amy Jane Foster, Bridget Louise Stocker, Mattheus Simon Maria Timmer, Sho Yamasaki
  • Patent number: 11464794
    Abstract: The present invention relates to an alginic oligosaccharic diacid composition comprising a mannuronic diacid of Formula (IV) or a pharmaceutically acceptable salt thereof, wherein n is an integer selected from 1 to 9, m is selected from 0, 1 or 2, m? is selected from 0 or 1, and wherein the total weight of alginic oligosaccharic diacid wherein n=1-5 accounts for more than 60% of the total weight of the composition; the total weight of guluronic acids accounts for less than 50% of the total weight of the composition.
    Type: Grant
    Filed: June 28, 2019
    Date of Patent: October 11, 2022
    Assignees: GREEN VALLEY (SHANGHAI) PHARMACEUTICALS CO., LTD., SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES
    Inventors: Meiyu Geng, Zhenqing Zhang, Yingshen Jin, Zhongping Xiao, Jian Ding
  • Patent number: 11406659
    Abstract: The present invention relates to the use of mannuronic diacid oligosaccharide composition in the treatment of inflammation.
    Type: Grant
    Filed: June 28, 2019
    Date of Patent: August 9, 2022
    Assignees: GREEN VALLEY (SHANGHAI) PHARMACEUTICALS CO., LTD., SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES
    Inventors: Meiyu Geng, Xianliang Xin, Zhenqing Zhang, Jian Ding
  • Patent number: 11406651
    Abstract: The present invention relates to the application of mannuronic diacid oligosaccharide composition in the treatment of vascular dementia.
    Type: Grant
    Filed: June 28, 2019
    Date of Patent: August 9, 2022
    Assignees: GREEN VALLEY (SHANGHAI) PHARMACEUTICALS CO., LTD., SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES
    Inventors: Meiyu Geng, Xianliang Xin, Xiaoguang Du, Zhenqing Zhang, Jian Ding
  • Patent number: 11406654
    Abstract: The present invention relates to the use of mannuronic diacid oligosaccharide composition in the treatment of Parkinson's disease.
    Type: Grant
    Filed: June 28, 2019
    Date of Patent: August 9, 2022
    Assignees: GREEN VALLEY (SHANGHAI) PHARMACEUTICALS CO., LTD., SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES
    Inventors: Meiyu Geng, Xianliang Xin, Xiaoguang Du, Zhenqing Zhang, Jian Ding
  • Patent number: 11406652
    Abstract: The present invention relates to the use of mannuronic diacid oligosaccharide composition in the treatment of diabetes.
    Type: Grant
    Filed: June 28, 2019
    Date of Patent: August 9, 2022
    Assignees: GREEN VALLEY (SHANGHAI) PHARMACEUTICALS CO., LTD., SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES
    Inventors: Meiyu Geng, Xianliang Xin, Zhenqing Zhang, Jian Ding
  • Patent number: 11389465
    Abstract: The present disclosure relates to phosphorylated hexaacyl disaccharide (PHAD) compounds, compositions, and methods for treating or preventing infections.
    Type: Grant
    Filed: May 1, 2018
    Date of Patent: July 19, 2022
    Assignee: Vanderbilt University
    Inventors: Edward Sherwood, Antonio Hernandez, Julia Bohannon
  • Patent number: 11306157
    Abstract: Methods for the preparation of oligosaccharide products from polysaccharide starting materials are disclosed. The methods include: hydrolyzing a glucosamine-containing polysaccharide starting material, such as heparin or heparosan, under conditions sufficient to form an oligosaccharide intermediate (e.g., a GlcN-IdoA disaccharide intermediate or a GlcA-GlcN disaccharide intermediate), and converting the oligosaccharide intermediate to the oligosaccharide product. Conversion of the oligosaccharide intermediates to the oligosaccharide products may include one or more esterification, acylation, epimerization, protection, and deprotection steps. Preparation of higher-order oligomers is described, as well as methods for selective oligosaccharide sulfation.
    Type: Grant
    Filed: December 20, 2019
    Date of Patent: April 19, 2022
    Assignee: California Institute of Technology
    Inventors: Linda C. Hsieh-Wilson, Nitin J. Pawar, Lei Wang
  • Patent number: 11292813
    Abstract: The present invention involves a novel aqueous iron composition. The aqueous iron composition includes iron sucrose and bicarbonate. The aqueous iron composition of the invention exhibits enhanced renal protective effects relative to conventional iron sucrose compositions.
    Type: Grant
    Filed: February 28, 2020
    Date of Patent: April 5, 2022
    Assignee: RENIBUS THERAPEUTICS, INC.
    Inventors: Donald Jeffrey Keyser, Alvaro F. Guillem, Richard A. Zager
  • Patent number: 11253533
    Abstract: Injectable Ivermectin solution is safely administrable to humans and animals used the disclosed technology. A macrocyclic lactone cyclodextrin complex which is completely dissolvable or dissolved in water in a ratio of at least 5 or 10 mg of macrocyclic lactone to 1 mL of water. The macrocyclic lactone cyclodextrin complex is non-toxic, without using organic solvents, and in embodiments, formed by adding a surfactant to the macrocyclic lactone complex to water. The macrocyclic lactone cyclodextrin complex is Ivermectin or an Ivermectin derivative in some embodiments. The cyclodextrin complex is 2-hydroxypropyl-beta-cyclodextrin in some embodiments of the disclosed technology. The surfactant can be polysorbate 80 and is in a ratio of 0.01% to 25%, by weight, to said water. The water soluble complexes can be added to the water. The water-soluble complexes can have at least one of an anti-parasitic, anti-viral and anti-cancer complex.
    Type: Grant
    Filed: June 30, 2021
    Date of Patent: February 22, 2022
    Assignee: MOUNTAIN VALLEY MD INC
    Inventor: Michael Farber
  • Patent number: 11230612
    Abstract: Embodiments of the present invention are directed to kits, compositions and methods for modifying and altering polysaccharide fillers and drug delivery systems with the application of hyaluronidase.
    Type: Grant
    Filed: February 16, 2018
    Date of Patent: January 25, 2022
    Assignee: Advanced Aesthetic Technologies, Inc.
    Inventor: Richard Burtt
  • Patent number: 11191806
    Abstract: Field of application: The invention relates to medicine and pharmacy and allows to obtain new pharmaceutical compositions based on polymyxin for the treatment of severe infectious diseases, but not possessing nephrotoxic properties in therapeutic doses. Technical result: New combined dosage forms based on the antibiotic polymyxin with low nephrotoxicity and high activity.
    Type: Grant
    Filed: May 4, 2018
    Date of Patent: December 7, 2021
    Inventors: Boris Farber, Ilya Ruvimovich Kleyn, Artur Viktorovich Martynov
  • Patent number: 11185554
    Abstract: The present invention is directed to methods for treating ebola virus infections or Marburg virus infections comprising administering to a subject an effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: September 14, 2017
    Date of Patent: November 30, 2021
    Assignees: EISAI R&D MANAGEMENT CO., LTD, THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM
    Inventors: Alexander Bukreyev, Fabian Gusovsky, Patrick Younan, Michael Everson
  • Patent number: 11187698
    Abstract: A living plant can function as self-powered auto-samplers and preconcentrators of an analyte within ambient groundwater, detectors of the analyte contained therein. For example, a pair of near infrared (IR) fluorescent sensors embedded within the mesophyll of the plant leaf can be used as detectors of the nitroaromatic molecules, with the first IR channel engineered through CoPhMoRe to recognize analyte via an IR fluorescent emission and the second IR channel including a functionalized nanostructure that acts as an invariant reference signal.
    Type: Grant
    Filed: December 2, 2016
    Date of Patent: November 30, 2021
    Assignee: MASSACHUSETTS INSTITUTE OF TECHNOLOGY
    Inventors: Michael S. Strano, Juan Pablo Giraldo Gomez, Seongyeon Kwak, Min Hao Wong
  • Patent number: 11179426
    Abstract: A delayed-release composition composed of a Lactobacillus bacterium, Bifidobacterium longum, Streptococcus thermophilus, inulin and xylooligosaccharide is provided for use in reducing nitrogenous waste products in the blood and treating renal failure.
    Type: Grant
    Filed: December 21, 2017
    Date of Patent: November 23, 2021
    Assignee: KIBOW BIOTECH, INC.
    Inventor: Natarajan Ranganathan
  • Patent number: 11142532
    Abstract: Disclosed herein are tricyclic compounds, including pyrimido[4?,5?:4,5]thieno[2,3-c]pyridazine-8-amine, pyrido[3?,2?:4,5]thieno[3,2-d]pyrimidine-4-amine, pyrazino[2?,3?:4,5]thieno[3,2-d]pyrimidin-4-amine, pyrido[3?,2?:4,5]furo[3,2-d]pyrimidin-4-amine, and pyrimido[4?,5?:4,5]furo[2,3-c]pyridazin-8-amine compounds, which may be useful as positive allosteric modulators of the muscarinic acetylcholine receptor M4 (mAChR M4). Also disclosed herein are methods of making the compounds, pharmaceutical compositions comprising the compounds, and methods of treating neurological and psychiatric disorders associated with muscarinic acetylcholine receptor dysfunction using the compounds and compositions.
    Type: Grant
    Filed: January 29, 2019
    Date of Patent: October 12, 2021
    Assignee: Vanderbilt University
    Inventors: Craig W. Lindsley, P. Jeffrey Conn, Darren W. Engers, Sean Bollinger, James C. Tarr, Paul Spearing, Julie L. Engers, Madeline Long, Thomas M. Bridges
  • Patent number: 11116736
    Abstract: This disclosure relates to methods of treating or preventing cystic fibrosis transmembrane conductance regulator (CFTR) mediated diseases such as cystic fibrosis, chronic obstructive pulmonary disease, chronic pancreatitis, chronic bronchitis, asthma, mucus formation, comprising administering an effective amount of a 2-amino-N?-benzylidene-acetohydrazide compound or derivative thereof to a subject in need thereof. In certain embodiments, the 2-amino-N?-benzylidene-acetohydrazide compound is ((E)-N?-(3,5-dibromo-2,4-dihydroxybenzylidene)-2-(m-tolylamino)acetohydrazide; or (E)-N?-(3,5-dibromo-2,4-dihydroxybenzylidene)-2-(p-tolylamino)acetohydrazide.
    Type: Grant
    Filed: January 3, 2020
    Date of Patent: September 14, 2021
    Assignees: Emory University, Bar-Ilan University, Children's Healthcare of Atlanta, Inc.
    Inventors: Nael McCarty, Guiying Cui, Hanoch Senderowitz, Netaly Khazanov
  • Patent number: 11091500
    Abstract: The present invention provides tricyclic compounds, and pharmaceutically acceptable salts thereof, having antimitotic activity, anti-multidrug resistance activity, for example P-glycoprotein inhibition, and antitumor activity, and which inhibit paclitaxel sensitive and resistant tumor cells. Also provided are methods of utilizing these compounds for treating tumor cells and inhibiting mitosis of cancerous cells.
    Type: Grant
    Filed: August 2, 2019
    Date of Patent: August 17, 2021
    Assignee: Duquesne University of the Holy Spirit
    Inventor: Aleem Gangjee
  • Patent number: 11046722
    Abstract: The present invention relates to sulphated disaccharides of formula (I) for use in the treatment of neuropathic pain. The present invention also relates to a pharmaceutical composition comprising the compound of formula (I) and at least one pharmaceutically acceptable excipient for use in the treatment of neuropathic pain. The compounds of formula (I) were effective in several experimental models of neuropathic pain for which reason these compounds can be used effectively for the treatment of different types of neuropathic pain and the clinical manifestations thereof, for example, mechanical allodynia or cold allodynia.
    Type: Grant
    Filed: March 6, 2018
    Date of Patent: June 29, 2021
    Assignees: BIOBERICA, S.A.U., UNIVERSIDAD AUTONOMA DE MADRID, FUNDACION TEOFILO HERNANDO
    Inventors: Josep Vergés Milano, Eulàlia Montell Bonaventura, Ramon Ruhí Roura, Carlos Raúl Aláez Versón, Antonio García García, Manuela García López, Juan Fernando Padín Nogueira, Marcos Maroto Pérez, Javier Egea Máiquez
  • Patent number: 11026961
    Abstract: An object is to provide a novel means for ameliorating mastitis or improving milk production. An ameliorating or therapeutic agent for mastitis that contains a biosurfactant, or a milk production promoting agent that contains a biosurfactant, is provided.
    Type: Grant
    Filed: December 18, 2017
    Date of Patent: June 8, 2021
    Assignees: HIROSHIMA UNIVERSITY, TOYOBO CO., LTD.
    Inventors: Shuhei Yamamoto, Masao Kitabayashi, Keiichi Hisaeda, Naoki Isobe
  • Patent number: 11020369
    Abstract: The present invention relates to the field of treating iron deficiency with IV iron carbohydrate complexes such ferric carboxymaltose, monitoring or identifying subjects to determine their eligibility for being administered said IV iron carbohydrate complexes, and combining said IV iron carbohydrate complexes with additional drugs in order to mitigate or reduce side effects induced by said IV iron carbohydrate complexes.
    Type: Grant
    Filed: March 18, 2020
    Date of Patent: June 1, 2021
    Assignee: PHARMACOSMOS HOLDING A/S
    Inventors: Tobias Sidelmann Christensen, Philip Schaffalitzky De Muckadell, Lars Lykke Thomsen, Claes Christian Strom
  • Patent number: 10994048
    Abstract: Provided is a hyaluronate fiber, and more particularly to a hyaluronate fiber, suitable for use in a surgical suture, a filler for cosmetic surgery, a lifting thread, a tissue-engineering scaffold, etc., and a method of manufacturing the same. Further, a method of manufacturing the hyaluronate fiber through melt spinning is provided, which includes (a) controlling the water content of a hyaluronate having a weight average molecular weight of 500˜3,000 kDa to 5˜20%, (b) producing a hyaluronate fiber by placing the hyaluronate having a controlled water content in a melt-spinning apparatus and performing heating to 150˜200° C. and then high-pressure spinning, and (c) hardening the surface of the hyaluronate fiber by immersing the hyaluronate fiber in an ethanol aqueous solution.
    Type: Grant
    Filed: September 1, 2016
    Date of Patent: May 4, 2021
    Assignee: JINWOO BIO CO., LTD.
    Inventors: Dong Keon Kweon, Seung Hyeon Park
  • Patent number: 10995053
    Abstract: A compound having the formula (I): is disclosed. Methods of preparing the compound of formula (I) are also disclosed. The compound of formula (I) can be prepared by reacting a compound of formula (II) with a compound of formula (III) in an organic solvent with EDC (1-ethyl-3-(3-dimethylaminopropyl)carbodiimide). The compound of formula (I) can also be prepared by reacting the compound of formula (II) with the compound of formula (III) in 1-ethyl-3-methylimidazolium hexafluorophosphate as a solvent with silicomolybdic acid as a catalyst.
    Type: Grant
    Filed: March 20, 2020
    Date of Patent: May 4, 2021
    Assignee: SHAANXI UNIVERSITY OF SCIENCE AND TECHNOLOGY
    Inventors: Han Li, Nan Hui, Bin Tian, Xingke Ju, Yuzhi Liu, Dan Yang, Jingwen Xu, Liang Qi, Qianqian Zhao, Yongbo Wang
  • Patent number: 10995067
    Abstract: Disclosed herein are novel uses of a polyhydroxylated pyrrolidine for the manufacture of a medicament for treating Fabry disease (FD). Accordingly, the present disclosure provides a method of treating a subject having or suspected of having FD. The method includes the step of, administering to the subject a therapeutically effective amount of a compound of formula (I), a salt, an ester or a solvate thereof, wherein: R1 is H, or C1-3 amine optionally substituted with —COR2; R2 is alkyl or alkene optionally substituted with cycloalkyl or phenyl having at least one substituent selected from the group consisting of, halo, alkyl, haloalkyl, and alkoxyl; so as to ameliorate, alleviate mitigate and/or prevent symptoms associated with the FD. According to preferred embodiments of the present disclosure, the compound of formula (I) is a chaperon of a mutated human lysosomal ?-galactosidase A (?-Gal A).
    Type: Grant
    Filed: June 14, 2017
    Date of Patent: May 4, 2021
    Assignee: ACADEMIA SINICA
    Inventor: Wei-Chieh Cheng
  • Patent number: 10993956
    Abstract: The present disclosure relates generally to compositions and methods for treating cancer with a glucopyranosyl lipid A (GLA) in the absence of antigen.
    Type: Grant
    Filed: May 20, 2019
    Date of Patent: May 4, 2021
    Assignee: Immune Design Corp.
    Inventors: Carlos V. Paya Cuenca, Jan Henrik Ter Meulen
  • Patent number: 10987368
    Abstract: The invention relates to HMOs and compositions comprising thereof for reducing the risk of, preventing, or treating CVD and/or CDV associated pathological conditions or diseases in humans, particularly in overweight and obese humans.
    Type: Grant
    Filed: June 15, 2016
    Date of Patent: April 27, 2021
    Assignee: Glycom A/S
    Inventors: Louise Kristine Vigsnæs, Bruce McConnell, Emma Elison
  • Patent number: 10918585
    Abstract: Provided is an anti-aging agent for skin which contains, as an active component, an inositol derivative in which a monosaccharide or an oligosaccharide is bonded to inositol, in which a total amount of the monosaccharide or the oligosaccharide bonded to one inositol molecule is 2 or greater in terms of monosaccharide unit.
    Type: Grant
    Filed: October 28, 2016
    Date of Patent: February 16, 2021
    Assignee: SHOWA DENKO K.K.
    Inventors: Yuko Nakagami, Shinji Yamaki, Ichiro Fujita, Tadashi Yoneda
  • Patent number: 10730902
    Abstract: The present invention relates to a compound of the general formula. The compound of formula is suitable for use in a method for treating a disorder relating to the binding of a galectin, such as galectin-3 to a ligand in a mammal, such as a human. Furthermore, the present invention concerns a method for treatment of a disorder relating to the binding of a galectin, such as galectin-3 to a ligand in a mammal, such as a human.
    Type: Grant
    Filed: November 8, 2016
    Date of Patent: August 4, 2020
    Assignee: GALECTO BIOTECH AB
    Inventors: Fredrik Zetterberg, Ulf Nilsson, Hakon Leffler, Anders Pedersen, Hans Schambye, Thomas Brimert, Richard Johnsson
  • Patent number: 10709694
    Abstract: The application describes treatment of hepatic encephalopathy using gastrointestinal specific antibiotics. One example of a gastrointestinal specific antibiotic is rifaximin.
    Type: Grant
    Filed: May 16, 2019
    Date of Patent: July 14, 2020
    Assignee: Salix Pharmaceuticals, Inc.
    Inventor: William Forbes
  • Patent number: 10689441
    Abstract: This invention relates generally to anti-Toll-like Receptor 4 (TLR4 antagonists) including antibodies that specifically bind Toll-like Receptor 4 (TLR-4), to methods of using the anti-TLR4 antagonists as therapeutics and to methods of using the anti-TLR4 antagonists for inhibiting, delaying the progression of, or otherwise ameliorating a symptom of Graft-versus-Host disease (GvHD) and/or improving survival of GvHD subjects and/or transplanted biological materials in subjects.
    Type: Grant
    Filed: December 8, 2014
    Date of Patent: June 23, 2020
    Assignee: NovImmune SA
    Inventors: Emmanuel Monnet, Limin Shang, Susana Salgado-Pires, Walter Ferlin, Greg Elson
  • Patent number: 10639346
    Abstract: The present invention derives from the finding that increased levels of Toll like receptor 4 (TLR4) is associated with liver failure and renal dysfunction and/or brain dysfunction and that by decreasing TLR4 levels in vivo, the kidney and brain consequences of liver disease that are precipitated by superimposed infection or inflammation may be reduced. Accordingly, the invention provides TLR4 antagonists for use in a method of treating an individual suffering from liver disease presenting with renal or brain dysfunction.
    Type: Grant
    Filed: January 8, 2018
    Date of Patent: May 5, 2020
    Assignee: Yaqrit Limited
    Inventors: Rajiv Jalan, Naina Shah
  • Patent number: 10624915
    Abstract: The present invention is directed to a dietary supplement comprising palatinose or a derivative thereof. The dietary supplement may be a nutritional product, a sports performance product, a weight loss product or a meal replacement product. The present invention is also directed to a method of increasing the absorption of a compound into the bloodstream, cells and tissue comprising administering palatinose, or a derivative thereof, in combination with the compound. The present invention also relates to a diluent for parenteral compounds. The diluent comprises palatinose or a derivative thereof. Another aspect of the present invention is directed to a method of decreasing the recovery time to pre-performance levels of total adenosine triphosphate (ATP) levels in a mammal comprising administering palatinose or a derivative thereof, to the mammal. The present invention is further directed to a method of supplying a compound to a diabetic patient, burn victim patient or trauma victim patient.
    Type: Grant
    Filed: August 1, 2017
    Date of Patent: April 21, 2020
    Inventor: Bruce W. Kneller
  • Patent number: 10555918
    Abstract: This disclosure relates to methods of treating or preventing cystic fibrosis transmembrane conductance regulator (CFTR) mediated diseases such as cystic fibrosis, chronic obstructive pulmonary disease, chronic pancreatitis, chronic bronchitis, asthma, mucus formation, comprising administering an effective amount of a 2-amino-N?-benzylidene-acetohydrazide compound or derivative thereof to a subject in need thereof. In certain embodiments, the 2-amino-N?-benzylidene-acetohydrazide compound is ((E)-N?-(3,5-dibromo-2,4-dihydroxybenzylidene)-2-(m-tolylamino)acetohydrazide; or (E)-N?-(3,5-dibromo-2,4-dihydroxybenzylidene)-2-(p-tolylamino)acetohydrazide.
    Type: Grant
    Filed: May 27, 2016
    Date of Patent: February 11, 2020
    Assignees: Emory University, Bar-Ilan University, Childern's Healthccare of Atlanta, Inc.
    Inventors: Nael McCarty, Guiying Cui, Hanoch Senderowitz, Netaly Khazanov
  • Patent number: 10543159
    Abstract: The present invention provides an agent for activating proliferation of follicle dermal papilla cells comprising an acidic saccharide alkaline earth metal salt, wherein the acidic saccharide is selected from the group consisting of a phosphorylated saccharide and lactobionic acid. The acidic saccharide is preferably a phosphorylated saccharide. The alkaline earth metal salt is preferably a calcium salt or a magnesium salt. In accordance with the present invention, the proliferation of follicle dermal papilla cells is promoted. Thus, the agent for activating proliferation of follicle dermal papilla cells is expected to produce hair-restoration and hair-growth effects such as treatment of hair thinning, prevention of hair loss, promotion of hair restoration, and promotion of hair growth.
    Type: Grant
    Filed: September 1, 2015
    Date of Patent: January 28, 2020
    Assignee: EZAKI GLICO CO., LTD.
    Inventor: Takatsugu Kobayashi
  • Patent number: 10464964
    Abstract: An Embodiment of the invention relates to a compound of the general formula. The compound of formula is suitable for use in a method for treating a disorder relating to the binding of a galectin, such as galectin-3 to a ligand in a mammal, such as a human. Furthermore an embodiment of the present invention concerns a method for treatment of a disorder relating to the binding of a galectin, such as galectin-3 to a ligand in a mammal, such as a human.
    Type: Grant
    Filed: January 14, 2016
    Date of Patent: November 5, 2019
    Assignee: Galecto Biotech AB
    Inventors: Fredrik Zetterberg, Ulf Nilsson, Hakon Leffler, Thomas Brimert, Richard Johnsson, Priya Verma
  • Patent number: 10350232
    Abstract: The present invention includes a concentration of at least 7.5% w/w saccharide other than trehalose, a preservative, in a buffered solution, wherein the composition is formulated for optic or otic administration. In certain embodiments, the composition is used to treat dry eyes, presbyopia, eye pain, blurred vision, confused mental function, scotoma, allergies, reduced craving for sugar, blocked tear ducts, tremors, vision and cognitive changes due to concussion, vertigo, TBI, loss of cognitive function as a result of traumatic brain injury, multiple sclerosis, Parkinson's disease, Alzheimer's disease, attention deficit disorder, attention deficit hyperactivity disorder, or Guillain-Barre syndrome.
    Type: Grant
    Filed: October 30, 2014
    Date of Patent: July 16, 2019
    Inventor: Peter D. Jaillet
  • Patent number: 10335397
    Abstract: The application describes treatment of hepatic encephalopathy using gastrointestinal specific antibiotics. One example of a gastrointestinal specific antibiotic is rifaximin.
    Type: Grant
    Filed: March 15, 2018
    Date of Patent: July 2, 2019
    Assignee: Salix Pharmaceuticals, Ltd
    Inventor: William Forbes
  • Patent number: 10336984
    Abstract: A novel class of agents has been identified to serve as cell-guard agents and/or target-specific supplements to increase cell quality and yield, as well as select for target cell populations. Several additive agents (both natural and synthetic) have been identified, including Vitamin D3, NAC, resveratrol, salubrinal, AKT, and tunicamycin (among others) that hold promise for application in cell models. In one embodiment, hypothermic stress regimes are utilized. In another embodiment, normothermic conditions are utilized while other stressors are tested in the processing. The methods of maintaining mass cell cultures and/or selecting out particular cell populations for further research and clinical use represents an important step in therapeutic discovery.
    Type: Grant
    Filed: August 6, 2015
    Date of Patent: July 2, 2019
    Assignee: CPSI Holdings LLC
    Inventors: John M. Baust, John G. Baust, William L. Corwin, Robert G. Van Buskirk
  • Patent number: 10294195
    Abstract: The invention provides a diamine crosslinking agent for acidic polysaccharides consisting of a diamine compound having a primary amino group at both terminals and an ester or thioester bond in the molecule, wherein the number of atom in the linear chain between at least one of the amino groups and the carbonyl carbon in the ester or thioester is 1 to 5; in particular, a diamine crosslinking agent for acidic polysaccharides which is represented by the general formula (I) below: [the symbols in the formula are as described in the specification]; a crosslinked acidic polysaccharide obtained by forming crosslinks by amide bonding between the amino groups in the diamine crosslinking agent and carboxyl groups in an acidic polysaccharide; and a medical material including the crosslinked product.
    Type: Grant
    Filed: January 30, 2015
    Date of Patent: May 21, 2019
    Assignee: Seikagaku Corporation
    Inventors: Sho Funayama, Yosuke Yasuda, Akihiro Takezawa, Katsuya Takahashi
  • Patent number: 10279042
    Abstract: The application of a highly controlled, micron-sized, branched, porous architecture to enhance the handling properties and degradation rate of hydrogels is described in the instant invention. A previously described pattern created through one-step nucleated crystallization in a hydrogel film creates tunable mechanical properties and/or chemical stability for use in tissue engineering applications. The bulk mechanical properties and the degradation rate of the material can be tuned easily by the addition or subtraction of crystalline structure or by the addition and subtraction of backfill material, making this useful for a variety of applications. Relevant mechanical properties that can be tuned through the application of this unique porosity are moduli, elasticity, tensile strength, and compression strength. The method of the present invention can be applied to biopolymers and natural materials as well as synthetic materials.
    Type: Grant
    Filed: January 23, 2015
    Date of Patent: May 7, 2019
    Assignee: Board of Regents, The University of Texas System
    Inventors: Sarah Mayes, Christine Schmidt
  • Patent number: 10279050
    Abstract: The invention provides a class of sucrose ester based cationic lipids and preparation method thereof. The vector prepared using the cationic lipid can be used to deliver nucleic acid. The sucrose ester based cationic lipid is prepared by using a chemical synthesis method in the invention, wherein the synthesis method is simple, and has a relatively high product yield. A composition, including suspension, emulsion, micelle and liposome and the like, can be prepared by mixing the sucrose ester based cationic lipid compound of the invention with a co-lipid. Sucrose ester based cationic lipid complex can be prepared by using the said composition and nucleic acid, which has advantages such as simple preparation, low toxicity and high transfection efficiency, and is a novel and highly efficient gene vector.
    Type: Grant
    Filed: June 25, 2015
    Date of Patent: May 7, 2019
    Assignee: DALIAN NATIONALITIES UNIVERSITY
    Inventors: Shubiao Zhang, Defu Zhi, Shaohui Cui, Yinan Zhao, Quan Zhou
  • Patent number: 10265312
    Abstract: A method of preventing post-operative endophthalmitis involves injecting a colored antibiotic solution into the anterior segment of the eye during surgery, the antibiotic solution having moxifloxacin, cefuroxime, vancomycin, or some combination thereof, and the coloring agent being preferably a cobalamin (e.g., cyanocobalamin).
    Type: Grant
    Filed: August 13, 2018
    Date of Patent: April 23, 2019
    Inventor: Jason Ahee
  • Patent number: 10188661
    Abstract: Described herein is a novel dosage regimen, and related uses and methods, for a prostaglandin FP receptor agonist (PFPRA) compound topically administered to the skin. The dosage regimen is useful for reduction of subcutaneous fat, for example, in patients who suffer from local excesses of subcutaneous fat. A particular advantage of the dosage regimen is the ability to reduce composition exposure and thereby promote convenience and comfort, while maintaining the desired exposure and therapeutic effect in subcutaneous fat. Further provided are kits according to the novel dosage regimen, comprising a PFPRA composition and instructions for use.
    Type: Grant
    Filed: June 24, 2015
    Date of Patent: January 29, 2019
    Assignee: Topokine Therapeutics, Inc.
    Inventors: Michael S. Singer, Murat V. Kalayoglu
  • Patent number: 10166200
    Abstract: An oxygen therapeutic composition, which includes a perfluorocarbon material having a boiling point of about 4 degrees Celsius to about 60 degrees Celsius, a lipid; a viscosity modifier; a buffer.
    Type: Grant
    Filed: June 8, 2017
    Date of Patent: January 1, 2019
    Assignee: NuvOx Pharma LLC
    Inventors: Evan C. Unger, Edmund R. Marinelli
  • Patent number: 10159635
    Abstract: The present invention provides cosmetic and pharmaceutical compositions and therapies capable of reducing skin pigmentation and valuable in treating and managing disorders of skin pigmentation. The invention uses safe and well tolerated non-digestible oligosaccharides as the active agents providing numerous advantages over the harsh chemicals of previously available compositions.
    Type: Grant
    Filed: March 19, 2013
    Date of Patent: December 25, 2018
    Assignee: Curapel (Scotland) Limited
    Inventors: Catherine O'Neill, Ralf Paus
  • Patent number: 10130583
    Abstract: The invention relates to a new powder composition which comprises in admixture: lactic acid, lactose and kaolin, wherein the amount of lactic acid is such that the pH of the powder composition should be within the range of about 3 to 4. Said powder composition may be use as a veterinary drug and in treating and/or preventing a disorder in the auditory canal of dogs and cats.
    Type: Grant
    Filed: April 14, 2014
    Date of Patent: November 20, 2018
    Assignee: Pegion Operations Limited
    Inventor: Claes Thulin
  • Patent number: 9937134
    Abstract: The present invention provides compositions suitable for topical administration to a mammalian subject including sodium hyaluronate and a pharmaceutically acceptable excipient. The present invention also provides methods for making and using the same.
    Type: Grant
    Filed: July 20, 2015
    Date of Patent: April 10, 2018
    Assignee: Cypress Pharmaceuticals, Inc.
    Inventor: Robert Lewis
  • Patent number: 9889176
    Abstract: The present invention derives from the finding that increased levels of Toll like receptor 4 (TLR4) is associated with liver failure and renal dysfunction and/or brain dysfunction and that by decreasing TLR4 levels in vivo, the kidney and brain consequences of liver disease that are precipitated by superimposed infection or inflammation may be reduced. Accordingly, the invention provides TLR4 antagonists for use in a method of treating an individual suffering from liver disease presenting with renal or brain dysfunction.
    Type: Grant
    Filed: August 17, 2011
    Date of Patent: February 13, 2018
    Assignee: YAQRIT LIMITED
    Inventors: Rajiv Jalan, Naina Shah
  • Patent number: 9854826
    Abstract: The invention discloses an oligosaccharide mixture comprising at least one N-acetyl-lactosamine, at least one sialylated oligosaccharide, and at least one fucosylated oligosaccharide. Food product, especially infant formula, comprising said oligosaccharide mixture.
    Type: Grant
    Filed: November 21, 2011
    Date of Patent: January 2, 2018
    Assignee: Nestec S.A.
    Inventors: Norbert Sprenger, Jean-Richard Neeser
  • Patent number: 9763969
    Abstract: The present invention describes compositions and related methods and kits for treating a variety of inflammatory conditions and infections. The therapeutic compositions include certain hyaluronidases capable of generating hyaluronan disaccharides when combined with hyaluronan, and/or the hyaluronan disaccharides themselves, and/or inflammatory hyaluronidase inhibitors. The invention further discloses the use of hyaluronidase inhibitors to treat certain infections in an individual.
    Type: Grant
    Filed: April 3, 2014
    Date of Patent: September 19, 2017
    Assignee: Cedars-Sinai Medical Center
    Inventors: George Liu, Pierre Kyme